Scientists restore partial sight in blind man

Published
4
Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques. — Reuters/File
Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques. — Reuters/File

PARIS: Scientists have for the first time managed to partially restore the sight of a blind patient by altering his cells, according to the results of a groundbreaking study published on Monday.

The technique known as optogenetics, which has been developed in the field of neuroscience over the last 20 years, involves genetically altering cells so they produce more light-sensitive proteins.

In some cases of blindness, known as inherited photoreceptor diseases, light-sensing cells in the retina that use proteins to deliver visual information to the brain via the optic nerve progressively degenerate.

Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques.

This involved injections in his eye and several months of stimulation with light emitting goggles, which transformed images of the visual world into light pulses projected into the retina in real time.

In a clinical first, they were able to restore partial sight for the 58-year old patient, leaving him able to recognise, count, locate and touch different objects laid out on a table in front of him.

Jose-Alain Sahel, lead study author from France’s Sorbonne University and National Centre for Scientific Research, said the trial provided proof-of-concept confirmation that it was possible to use optogenetics to restore sight in humans.

“Importantly, blind patients with different kinds of neurodegenerative photoreceptor disease and a functional optic nerve will potentially be eligible for the treatment,” he said.

“However, it will take time until this therapy can be offered to patients,” added Sahel, who is also a professor at the University of Pittsburgh School of Medicine’s Department of Ophthalmology.

Published in Dawn, May 25th, 2021

Opinion

Editorial

Swat bombing
Updated 04 Aug, 2026

Swat bombing

IT is a bitter irony that terrorists struck a protest against violence in Swat on Sunday, causing at least 17...
Tariff blow
04 Aug, 2026

Tariff blow

FOR an export sector already squeezed by high production costs, the additional 10pc tariff on top of the existing...
Perilous peaks
04 Aug, 2026

Perilous peaks

THE deaths of 10 climbers in an avalanche on Broad Peak is a sad reminder of the perils that many mountaineers face...
Farewell to arms?
Updated 03 Aug, 2026

Farewell to arms?

PALESTINIAN resistance group Hamas recently made a major concession by agreeing to give up its weapons. It should be...
Unplanned future
03 Aug, 2026

Unplanned future

A PROJECTION that Pakistan’s population could reach 400m by 2040 should not be treated as another dramatic number...
No more torture
03 Aug, 2026

No more torture

EVEN the best laws on the books are worth little unless the state shows the willingness to enforce them. This is...